36 min listen
Gene Therapy For Chronic Inflammation With Xalud's Howard Rutman, M.D.
Gene Therapy For Chronic Inflammation With Xalud's Howard Rutman, M.D.
ratings:
Length:
47 minutes
Released:
Dec 12, 2022
Format:
Podcast episode
Description
While many gene therapy development efforts focus on rare disease, Xalud Therapeutics is taking a swing that, measured in addressable patient market terms, is considerably bigger. Osteoarthritis, or OA, is a chronic, progressive joint disease that affects over 30 million people in the United States. On this episode of the Business of Biotech, we catch up with Xalud Chief Medical Officer Howard Rutman, M.D., MBA for a discussion on the company's late-stage plasmid DNA gene therapy that's showing promise in OA and other chronic inflammatory conditions. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!
Released:
Dec 12, 2022
Format:
Podcast episode
Titles in the series (100)
002: The Biopharma Exit Strategy With Dr. Francois Nader by Business Of Biotech